These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9437543)

  • 1. Correlation between serum cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non-small cell lung cancer.
    Kashiwabara K; Nakamura H; Kiguchi T; Yagyu H; Kishi K; Wei BR; Yoneyama K; Matsuoka K
    Clin Chim Acta; 1997 Oct; 266(2):149-55. PubMed ID: 9437543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical equivalence of two cytokeratin markers in mon-small cell lung cancer: a study of tissue polypeptide antigen and cytokeratin 19 fragments.
    Buccheri G; Torchio P; Ferrigno D
    Chest; 2003 Aug; 124(2):622-32. PubMed ID: 12907552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
    Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ
    Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between serum cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non-malignant diseases.
    Kashiwabara K; Nakamura H; Kiguchi T; Matsuoka T
    Clin Chim Acta; 1998 May; 273(1):35-42. PubMed ID: 9620468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
    Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
    Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer.
    Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Massaron S; Cataldo I; Oldani S; Iurlo A; Caldiera S; Bombardieri E
    Int J Biol Markers; 1999; 14(2):92-8. PubMed ID: 10399628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.
    Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y
    Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer.
    Stieber P; Dienemann H; Hasholzner U; Müller C; Poley S; Hofmann K; Fateh-Moghadam A
    Eur J Clin Chem Clin Biochem; 1993 Oct; 31(10):689-94. PubMed ID: 7507359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of cytokeratin 19 expression in tumor tissue and serum CYFRA 21-1 levels in non-small cell lung cancer.
    Kosacka M; Jankowska R
    Pol Arch Med Wewn; 2009; 119(1-2):33-7. PubMed ID: 19341176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tumor markers TPA and Cyfra 21.1 in patients with non-small cell lung cancer after surgery and chemotherapy].
    Passowicz-Muszyńska E; Gisterek I; Marciniak M; Kornafel J; Kołodziej J; Jankowska R
    Pol Merkur Lekarski; 2002 Oct; 13(76):294-7. PubMed ID: 12557434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1.
    van der Gaast A; Schoenmakers CH; Kok TC; Blijenberg BG; Cornillie F; Splinter TA
    Br J Cancer; 1994 Mar; 69(3):525-8. PubMed ID: 7510117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
    Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
    Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer.
    Trevisani L; Putinati S; Sartori S; Abbasciano V; Bagni B
    Chest; 1996 Jan; 109(1):104-8. PubMed ID: 8549168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer.
    Bates J; Rutherford R; Divilly M; Finn J; Grimes H; O'Muircheartaigh I; Gilmartin JJ
    Eur Respir J; 1997 Nov; 10(11):2535-8. PubMed ID: 9426091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokeratins as serum markers in egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS.
    Mady EA
    Int J Biol Markers; 2001; 16(2):130-5. PubMed ID: 11471896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
    Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
    Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Cyfra 21-1, TPA and SCC tumor markers in esophageal squamous cell carcinoma.
    Quillien V; Raoul JL; Laurent JF; Meunier B; Le Prise E
    Oncol Rep; 1998; 5(6):1561-5. PubMed ID: 9769406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer.
    Gaarenstroom KN; Bonfrer JM; Kenter GG; Korse CM; Hart AA; Trimbos JB; Helmerhorst TJ
    Cancer; 1995 Sep; 76(5):807-13. PubMed ID: 8625184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?
    Nisman B; Lafair J; Heching N; Lyass O; Baras M; Peretz T; Barak V
    Cancer; 1998 May; 82(10):1850-9. PubMed ID: 9587116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
    Ebert W; Hoppe M; Muley T; Drings P
    Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.